Last reviewed · How we verify
Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo
The primary objective of this study is to compare efficacy and safety of two formulations of teriparatide 20 mcg/day plus calcium and vitamin D in postmenopausal women with osteoporosis.
Details
| Lead sponsor | Bio Sidus SA |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 110 |
| Start date | 2013-06 |
| Completion | 2014-11 |
Conditions
- Postmenopausal Osteoporosis With Pathological Fracture
Interventions
- Teriparatide (rDNA origin)
Primary outcomes
- Change from baseline in Bone mineral Density at 6 months. — Basal, Six months and One Year
Countries
Argentina